Our data also highlight that the recognition of GU-rich sequences of the SARS-CoV-2 genome function as specific TLR8 ligands in neutrophils, in turn indicating that the use of specific TLR8 inhibitors might serve for counteracting the excessive inflammatory responses observed in severe COVID-19 patients, at least those promoted by neutrophils. The gene discussed is TLR8; the disease is COVID-19.